Summary
Gilead Sciences, Inc. reported solid financial performance for the second quarter of fiscal year 2025, with total revenues reaching $7.08 billion, a 2% increase year-over-year. This growth was primarily driven by strong performance in the HIV segment, particularly from Biktarvy and Descovy sales, which saw significant increases. The company also experienced growth in Trodelvy sales within its Oncology segment. Net income attributable to Gilead surged by 21% to $1.96 billion, with diluted earnings per share rising to $1.56. This improvement was bolstered by higher product sales and a favorable swing in unrealized gains on equity securities compared to the prior year. However, the company did incur a $190 million impairment charge related to its bulevirtide IPR&D intangible asset due to increased market competition. Despite this, Gilead's robust product sales, particularly in HIV, and a more favorable equity investment performance contributed to a strong quarter.
Financial Highlights
55 data points| Revenue | $7.08B |
| Cost of Revenue | $1.50B |
| Gross Profit | $5.58B |
| SG&A Expenses | $1.36B |
| Operating Expenses | $4.61B |
| Operating Income | $2.47B |
| Net Income | $1.96B |
| EPS (Basic) | $1.57 |
| EPS (Diluted) | $1.56 |
| Shares Outstanding (Basic) | 1.25B |
| Shares Outstanding (Diluted) | 1.25B |
Key Highlights
- 1Total revenues grew 2% to $7.08 billion for Q2 2025, driven by strong HIV product sales.
- 2HIV product sales increased by 7% to $5.09 billion, with Biktarvy up 9% and Descovy up 35%.
- 3Trodelvy sales saw a 14% increase, reaching $364 million for the quarter.
- 4Net income attributable to Gilead increased 21% to $1.96 billion.
- 5Diluted EPS rose to $1.56, a 21% increase compared to the prior year's quarter.
- 6A $190 million impairment charge was recognized for bulevirtide IPR&D assets due to increased market competition.
- 7Cash and cash equivalents stood at $5.14 billion as of June 30, 2025.